Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931017 · ClinicalTrials.gov registry record · Phase 2
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
A Phase 2 study of Lung Carcinoma, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT04931017 is a Phase 2 study of Lung Carcinoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 50 participants, below the 5,042-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04931017, a Phase 2 study of Lung Carcinoma, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. At similar dosage, the drug may have potential anti-cancer activity. Metformin use has been associated with improved survival in patients with non-small cell lung carcinoma, a specific type of lung cancer, and it has also been shown to enhance immune mobilization against tumors. This trial aims to see whether metformin extended release as a preventative treatment may lower the chance of developing lung cancer, and whether it may help patients' immune system learn ("reprogram") to lower a certain type of immune cell (called regulatory T cells) that are linked to tumor development.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
- OTHER Questionnaire Administration
- PROCEDURE Bronchoscopy
- DRUG Extended Release Metformin Hydrochloride
Study Locations (4)
British Columbia
- BC Cancer Research Centre - Vancouver
- University of British Columbia Hospital - Vancouver
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04931017
The ClinicalTrials.gov registry entry for NCT04931017 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,042-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04931017 reports 4 study locations spanning 3 distinct geographic areas - top geographies include British Columbia, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT04931017 about?
NCT04931017 is a clinical study titled "Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer". This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. ...
What is the current status of trial NCT04931017?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-09-09. Estimated completion is 2027-06-30.
What conditions does trial NCT04931017 study?
This clinical trial studies the following conditions: Lung Carcinoma.
What interventions are being tested in trial NCT04931017?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE), Questionnaire Administration (OTHER), Bronchoscopy (PROCEDURE), Extended Release Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04931017?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04931017 being conducted?
This trial has 4 study locations across Colorado, New York, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
RECRUITING · Phase 2
-
Evaluation of Canakinumab in High-Risk Former-Smokers
ACTIVE NOT RECRUITING · Phase 2
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
The Rise in Robotic Atypical Segmentectomies
RECRUITING
-
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
RECRUITING
-
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.